<unk>  (USAN; ), sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog's skin (subcutaneous), in particular areas of a dog's leg. Stelfonta is injected directly into the MCT (intratumoral injection). Stelfonta works by activating a protein that spreads throughout the treated tumor, which disintegrates tumor cells. It is a tiglien-3-on derivative, with a tiglian backbone. Since the substance is obtained by extraction, impurities with other tiglian-3-one derivatives are possible. The synthesis is only used to confirm the structure and is possible via the Wender synthesis.<unk>  was approved for use in dogs in the European Union in January 2020. It is indicated for the treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumors located at or distal to the elbow or the hock, and non-resectable, non metastatic cutaneous mast cell tumors in dogs.
Tigilanol tiglate
Tetramethyl bisphenol F
Chlorotrianisene
Amylmetacresol
Roxatidine acetate
Desmethylchlorotrianisene
Naftalan oil
Epiestriol